<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - VITAMIN K ANTAGONISTS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>VITAMIN K ANTAGONISTS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Should not be given in the first trimester of pregnancy.</p><p>Warfarin, acenocoumarol, and phenindione cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery. Therefore, if at all possible, they should be avoided in pregnancy, especially in the first and third trimesters (difficult decisions may have to be made, particularly in women with prosthetic heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism).</p><p>Stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid use within 48 hours postpartum</li>
            <li>haemorrhagic stroke</li>
            <li>significant bleeding</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Alopecia, diarrhoea, haemorrhage, hepatic dysfunction, jaundice, nausea, pancreatitis, purpura, pyrexia, rash, skin necrosis (increased risk in patients with protein C or protein S deficiency), vomiting, &#8216;purple toes&#8217;,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
                <h3>Treatment Booklets</h3>
              <p>Anticoagulant treatment booklets should be issued to all patients or their carers; these booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information. In <b>England</b>, <b>Wales</b>, and <b>Northern Ireland</b>, they are available for purchase from:</p><ul outputclass="organization">
            <li outputclass="thoroughfare">Gorse Street, Chadderton</li>
            <li outputclass="thoroughfare">Oldham</li>
            <li outputclass="postalcode">OL9 9QH</li>
            <li outputclass="contactnumber">Tel: 0845 610 1112</li>
            </ul><p>GP practices can obtain supplies through their Local Area Team stores. NHS Trusts can order supplies from <xref format="html" href="http://www.nhsforms.co.uk">www.nhsforms.co.uk</xref>or by emailing nhsforms@mmm.com.</p><p>In <b>Scotland</b>, treatment booklets and starter information packs can be obtained by emailing stockorders. dppas@theapsgroup.com or by fax on (0131) 6299 967</p><p>Electronic copies of the booklets and further advice are also available at <xref format="html" href="http://www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant">www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant</xref>.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Bacterial endocarditis (use only if warfarin otherwise indicated)
          </li>
          <li>
            conditions in which risk of bleeding is increased
          </li>
          <li>
            history of gastrointestinal bleeding
          </li>
          <li>
            peptic ulcer
          </li>
          <li>
            postpartum (delay warfarin until risk of haemorrhage is low&#8212;usually 5&#8211;7 days after delivery)
          </li>
          <li>
            recent ischaemic stroke
          </li>
          <li>
            recent surgery
          </li>
          <li>
            uncontrolled hypertension
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Women of child-bearing age should be warned of the danger of teratogenicity.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.</p><p>It is essential that the INR be determined daily or on alternate days in early days of treatment, <i>then</i> at longer intervals (depending on response), <i>then</i> up to every 12 weeks.</p><p>Change in patient&#8217;s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing.</p>
            </section>
      </section>











      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of VITAMIN K ANTAGONISTS</h2>

          <ul>
            <li><a href="../drug/PHP1494.html">WARFARIN SODIUM</a></li>
            <li><a href="../drug/PHP1499.html">ACENOCOUMAROL</a></li>
            <li><a href="../drug/PHP1501.html">PHENINDIONE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
